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ABSTRACT 
Objective: The aim of the present work was to develop and characterize mucoadhesive film of spray dried Lovastatin (LVS) for buccal delivery to 
enhance bioavailability.  
Methods: Mucoadhesive films were prepared by solvent casting technique by using different polymers HPMCK4M, HPMC E5LV and chitosan. The 
successful patches were evaluated for film thickness, weight, content uniformity, surface pH, swelling index, folding endurance, ex-vivo residence 
time, ex-vivo bioadhesion test, in vitro drug release, ex-vivo drug permeation and stability study.  
Results: The thickness of all prepared patches ranged from 0.21±0.07 to 1.5±0.39 mm, the weight of the film 89.10±0.6 to 128.57±0.3 mg, drug 
content 85.47±0.87 to 97.33±0.31%, surface pH 5.6±0.67 to 7.6±0.98, swelling index 23.0±4.1 to 76.5±3.6%, folding endurance 165±1.9 to 350±2.5 
respectively. Ex-vivo residence time ranged from 2.2±0.08to 8.2±0.17 h and ex-vivo bioadhesive strength 30±0.64 to 66±0.43 g. The formulations 
with HPMC E5 shown short period of residence time and shows weak force of adhesion., which might be because of low viscosity of the polymer 
which resulted into weak adhesion. The percentage drug release and ex-vivo drug permeation was in the following descending order HPMC 
K4M>HPMC E5LV>chitosan. These results confirm the extension of drug release in case of ionic polymer chitosan. The kinetics data shows that drug 
release and permeation follows nonfiction diffusion. Accelerated stability data revealed that there is no significant change in drug content, in vitro 
drug release and ex-vivo permeation. 
Conclusion: It can be concluded that mucoadhesive buccal patch is a promising dosage form to enhance the drug bioavailability by preventing first-
pass metabolism thus providing better therapeutic efficacy.  
Keywords: Lovastatin, HPMCK4M, HPMC E5LV, Chitosan, Ex-vivo bioadhesion, Swelling index, Ex-vivo permeation 




The oral drug delivery is considered to be the most preferred 
route by majority of the patients amongst the various available 
routes of drug delivery. However, oral administration of drugs has 
certain disadvantages such as hepatic first-pass metabolism and 
enzymatic degradation within the GI tract that prohibits oral 
administration of various classes of drugs [1]. Since last three 
decades researchers have been focusing on buccal drug delivery, 
as it has shown ability to enhance the therapeutic efficacy of 
poorly effective oral drugs [2]. The direct entry of the drug into the 
systemic circulation avoids the first-pass hepatic metabolism 
leading to increase in bioavailability. Other advantages are low 
enzymatic activity, painless administration, easy drug withdrawal, 
facility to include permeation enhancers/enzyme inhibitors or pH 
modifiers in the formulation and versatility in designing as 
multidirectional or unidirectional release systems for local or 
systemic actions. Various mucoadhesive formulations were 
suggested for buccal delivery that includes buccal patches, 
adhesive tablets, and adhesive gels. However, buccal films are 
preferred over adhesive tablets in terms of flexibility and comfort 
[3]. Mucoadhesive formulations use polymers as adhesive 
components. These polymers form viscous liquids when hydrated, 
increasing their retention time over mucosal surfaces which may 
lead to interaction between polymers chain and the oral mucosa. 
Thus, the adequate selection of the polymer is crucial for the 
correct delivery of drugs in mucoadhesive formulations [4]. 
Lovastatin (LVS) is an antihyperlipidaemic drug. Its principal 
metabolite that is hydroxy acid is potent inhibitor of 3-hydroxy-3-
methylglutaryl coenzyme A (HMGCoA) reductase, which catalyses 
the conversion of hydroxy methyl gluterate to mevalonate which is 
an early and rate limiting step in biosynthesis of cholesterol [5]. It 
has been proven that LVS is effective as therapeutic and prophylactic 
agent in the management of major morbidities such as 
atherosclerosis, peripheral artirial disease and cardiovascular 
disease [6]. The drug lovastatin possesses some major limitations 
such as low solubility, less bioavailability (5%), short half-life (1.1-
1.7 h), excretion in the bile (85%), gastrointestinal side effects 
To overcome the 
[7]. It 
is a white crystalline powder which has low aqueous solubility, 
which is 0.4 µg/ml at room temperature [8]. 
low aqueous solubility of 
In the current study, the solid dispersions (prepared by spray 
drying technique SD4) showing best in-vitro drug release profile 
is selected and further developed into transbuccal patches, 
which helps to facilitate drug absorption through transbuccal 
route and overcome the other problems such as first-pass 
metabolism, excretion in the bile and other side effects. Hence by 
formulating spray-dried lovastatin into transbuccal films, an 
attempt has been made to improve the bioavailability of the drug 
LVS. 
model drug LVS an 
attempt has been made to enhance the aqueous system solubility 
of LVS by preparing solid dispersion by spray drying technique 
by using PVPK30 polymer. The result findings are published in 
our previous paper “Physicochemical characterization and 
dissolution study of spray-dried amorphous Lovastatin with 
PVPK30”; The Pharma Innovation journal; 7(3)2018:498-502. 
MATERIALS AND METHODS 
Materials 
LVS is obtained as gift sample by Biocon Limited, Bangalore 
Karnataka India. HPMCK4M by Yarrow chemical products Mumbai 
Maharashtra India and chitosan from Central Institute of fischeries 
technology Cochin, Kerala India. All other chemicals and solvents 
used in this study were of analytical grade reagents. 
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Compatibility studies were carried out for SD4 and polymers used to 
prepare the transbuccal film. SD4, HPMC K4M, HPMC E5LV, chitosan 
polymers and transbuccal films were subjected for Infrared 
spectroscopic analysis. 
Fourier transform infrared spectra of moisture-free powdered 
samples were obtained by using spectrophotometer (FT-IR 
Shimadzu Co., Japan) by potassium bromide (KBr) pellet method (2 
mg of sample in 200 mg of KBr). The scanning range was 400-4000 
cm-1 and the resolution was 1 cm-1
The solvent casting technique was used for the preparation of 
spray-dried LVS mucoadhesive buccal patches. The buccal 
patches were formulated by using different polymers i.e., 
HPMCK4M, HPMC E5LV and chitosan. These polymers were 
chosen from a series of trials on the base of the chemical 
compatibility, organoleptic properties and adhesiveness 
property. The placebo films were prepared. The processing 
variables used while formulating the placebo patches were the 
concentration of polymers and plasticizers. After results of 
placebo films were found to be satisfactory, the formulations 
containing different concentrations of polymers were prepared 
by using above-said polymers. 
. 
Formulation of transbuccal films 
Transbuccal film by using HPMC K4M 
The polymer HPMCK4M is dissolved in 10 ml of mixture of ethanol 
and distilled water (3:2) and soaked for overnight. The polymeric 
solution was stirred on magnetic stirrer for 2 h. The solid dispersion 
equivalent to 120 mg LVS was added followed by addition of 
plasticizer 4 % glycerol and 20 mg of menthol as permeation 
enhancer. The mixture was stirred for 30 min and then poured into 
Petri dish, which is stored at 4 °C to remove air bubbles entrapped 
and finally dried at 37 °C for 4 h. The dried films were cut into 1 cm2
 
 
and packed in aluminum foil and stored [1, 4, 9]. 
Table 1: Composition of the transbuccal film by using HPMC K4M 




F1 120 100 5 20 
F2 120 200 5 20 
F3 120 300 5 20 
F4 120 400 5 20 
F5 120 500 5 20 
F6 120 600 5 20 
 
Transbuccal film by using HPMC E5  
The polymer HPMC E5 is dissolved in 10 ml of a mixture of 
dichloromethane and ethanol (1:1) and soaked for overnight. The 
polymeric solution was stirred on magnetic stirrer for 2 h. The 
solid dispersion equivalent to 120 mg LVS was added followed by 
addition of plasticizer 0.7 % glycerol and 20 mg of menthol as 
permeation enhancer. The mixture was stirred for 30 min and 
then poured into Petri dish, which is stored at 4 °C to remove air 
bubbles entrapped and finally dried at 37 °C for 4 h. The dried 
films were cut into 1 cm2
 
 and packed in aluminum foil and stored 
[4, 10]. 
Table 2: Composition of transbuccal film by using HPMC E5 
Formulation code Solid dispersion equivalent to LVS (mg) HPMC E5 (mg) Plasticizer 
Glycerol (%) 
Permeation enhancer menthol (mg) 
F7 120 100 0.7 20 
F8 120 200 0.7 20 
F9 120 300 0.7 20 
F10 120 400 0.7 20 
F11 120 500 0.7 20 
F12 120 600 0.7 20 
 
Transbuccal film by using chitosan 
Citric acid 20 mg was dissolved in water. To this solution, chitosan 
polymer was added and soaked for overnight. The polymeric 
solution was stirred on magnetic stirrer for 2 h. The solid dispersion 
equivalent to 120 mg LVS was added. The mixture was stirred for 30 
min and then poured into petridish, which is stored at 4 °C to remove 
air bubbles entrapped. The patches were finally dried at 25 °C for 24 h. 
The dried films were cut into 1 cm2
 
 and packed in aluminium foil 
and stored [4]. 
Table 3: Composition of the transbuccal film by using chitosan 
Formulation code Solid dispersion equivalent to LVS (mg) Chitosan (mg) Plasticizer 
Glycerol (%) 
Permeation enhancer citric acid (mg) 
F13 120 100 3 20 
F14 120 200 3 20 
F15 120 300 3 20 
F16 120 400 3 20 
F17 120 500 3 20 
F18 120 600 3 20 
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Physicochemical characteristics of transbuccal patches 
Film thickness and weight 
The thickness of all the formulations was measured by screw gauge 
(Mitutoyo Corporation, Kavasaki, Japan) and the weight of these 
films were determined by using electronic balance [1]. 
Content uniformity 
The film was dissolved in 100 ml isotonic phosphate buffer pH 
6.8±0.2, filtered (0.22 µm), and resultant solutions were analyzed by 
UV Spectrophotometer at 238 nm. The experiment was performed in 
triplicate [1]. 
Surface pH 
The microenvironmental pH of all the formulations was measured so 
as to predict its effect on buccal mucosa. The formulations were first 
wetted by adding distilled water to its surface. The surface pH was 
then recorded by bringing a glass electrode near the surface of the 
formulation and allowing it to equilibrate for 1 min. The average 
pH±SD was determined for all formulations [1]. 
Swelling index 
The buccal patches were weighed individually (designated as W1) 
and placed seperately in 2% agar gel plates, incubated at 37±1 °C 
and examined for any physical changes. At regular 1 h time intervals 
until 3 h, films were removed from the gel plates and excess surface 
water was removed carefully using the filter-paper. The swollen 
films were then reweighed (W2
 
The experiment was performed in triplicate and average±SD values 
were recorded [1]. 
Folding endurance 
Folding endurance of the films was determined by repeatedly 
folding and unfolding the films at the same place till it broke or for 
300 times, which is considered to be a satisfactory value to reveal 
good folding-endurance properties. The number of times the film 
could be folded at the same place without breaking gave the value of 
the folding endurance [1]. 
Ex-vivo residence time/adherence time 
The ex-vivo residence time is studied (n=3) to know the time 
required for complete erosion and/or detachment of the film from 
the mucosa surface. The fresh goat mucosa is fixed to the inner side 
of the beaker about 2.5 cm from the bottom. One side of the film was 
wetted with 1 drop of phosphate buffer pH 6.8 and it is adhered to 
the surface of the buccal mucosa by applying slight force with 
fingertips for 30 s. The beaker was filled with 500 ml of phosphate 
buffer pH 6.8 and was kept at 37±0.5 °C. After 2 min, a 50 rpm 
stirring rate is applied to simulate the buccal cavity environment 
and film adherence is monitored for 8 h [1]. 
Ex-vivo bioadhesion test 
) and the swelling index (SI) was 
calculated using the following formula:  
Modified physical balance method is used to measure the ex-vivo 
mucoadhesive strength of prepared films. Fresh goat’s buccal 
mucosa is taken and cut into piece and washed with phosphate 
buffer pH 6.8 and tied to the open mouth of glass vial which is tightly 
fitted into a glass beaker which is filled with phosphate buffer pH 6.8 
in such way that, it just touched the buccal surface. The temperature 
of this beaker is maintained at 37 °C±1 °C. The film is adhered to the 
lower side of a rubber stopper with cyanoacrylate adhesive. Two 
pans of the balance are balanced with 5g weight on the right side of 
the pan, which is lowered the pan along with the film over the 
mucosa. The balance is kept in this position for 5 min of contact 
time. The water drops are added slowly to the right-hand side pan, 
until the film detached from the mucosal surface. The weight 
required to detach the film from the mucosal membrane surface is a 
measure of mucoadhesive strength. All the experiments are 
performed in triplicates and mean±SD are reported. The following 
formula is used to calculate the detachment force [1].  
Force of adhesion (N) = (g X 9.81)/ 1000 
Detachment force (N/m2) = Force of adhesion (N) / Surface area 
(m2) 
In vitro drug release study 
In vitro drug release is carried out by paddle over disc dissolution 
apparatus. The transbuccal patch is placed beneath the disc in the 
dissolution jar containing 900 ml phosphate buffer (pH 6.8) solution. 
The bath temperature is maintained at 37±1 °C with 50 rpm speed. 
Aliquots of 5 ml are withdrawn at prespecified time intervals for 6 h. 
same volume of fresh buffer solution is replaced. The withdrawn 
sample solution is filtered through 0.4 µm membrane filter and the 
amount of drug is determined by measuring the absorbance of the 
aliquots at 238 nm using UV spectrophotometer and percentage 
drug release were plotted [1]. 
Ex-vivo drug permeation study 
Franz diffusion cell is used to carry out ex-vivo drug permeation 
study. Fresh goat buccal mucosa is fixed on a diffusion cell between 
the donor and receptor compartment. The transbuccal patch is fixed 
on the mucosal membrane. Five ml of phosphate buffer pH 6.8 in the 
donor compartment and 45 ml of the phosphate buffer pH 6.8 in the 
receptor compartment is filled as dissolution fluid. The fluids 
maintained at 37±1 °C and stirred continuously at speed of 50±5 
rpm. Aliquots of 1 ml of the sample are withdrawn at prespecified 
time interval. Same volume of fresh buffer solution is replaced. The 
withdrawn sample solution is filtered through 0.4 µm membrane 
filter and the amount of drug is determined by measuring the 
absorbance of the aliquots at 238 nm using UV spectrophotometer 
and percentage drug permeated were plotted [1]. 
Stability study 
The accelerated stability of optimized formulation F3 is conducted 
as per ICH guidelines at 40 °C/75% RH up to 6 mo. Periodically 
samples are removed (initial, 1 mo, 2 mo, 3 mo) and analyzed for 
drug content, in vitro release and ex-vivo permeation [9]. 
RESULTS AND DISCUSSION 
Compatibility studies 
The IR Spectra of SD4 (SDSP) and transbuccal formulations (SD-
HPMCK4M, SD-HPMCE5LV and SD-chitosan) are shown in the fig. 1. 
Upon comparison of IR Spectra of SD4(SDSP) and transbuccal 
formulations(SD-HPMCK4M, SD-HPMCE5LV and SD-chitosan), it was 
found that the characteristic peaks of LVS in SD4 were 3535 cm-
1(alcohol OH stretch), 3016 cm-1 (olefinic CH stretching vibrations) 
1725 cm-1and 1695 cm-1 
The physicochemical charecteristics data of transbuccal patches are 
shown in the tables (4-6) below. 
(lactone and ester carbonyl stretch) also 
found in transbuccal formulations along with characteristic peaks of 
respective polymers. It can be concluded by these observations that 
there are no possible interactions between the SD4 and polymers. 
Formulation of transbuccal films 
The formulations containing different concentrations of polymers 
were prepared and their effects on physicochemical characteristics 
were studied. However, the selections of plasticizer were finalized 
during placebo film preperation. 
Physicochemical charecteristics of transbuccal patches 
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Fig. 1: FTIR spectra of SD4 (SDSP) and transbuccal formulations (SD-HPMCK4M, SD-HPMCE5LV and SD-Chitosan) 
 
Table 4: Physicochemical characteristics of transbuccal film by using HPMC K4M (F1-F6) 
Formulation code Thickness 
(mm)






* Swelling index (%)
 
* Folding endurance* 
F1 0.27±0.05 91.91±0.2 91.71±0.33 6.2±0.07 31.7±3.5 315±7.5 
F2 0.34±0.02 101.25±0.3 93.23±0.41 6.4±0.05 42.9±5.1 312±5.0 
F3 0.51±0.04 108.32±0.4 95.75±0.56 6.7±0.04 56.0±2.1 350±2.5 
F4 0.62±0.01 115.56±0.2 94.80±0.61 6.4±0.12 57.9±2.8 340±6.0 
F5 0.68±0.03 125.46±0.6 91.68±0.23 6.3±1.23 49.4±1.8 324±4.5 
F6 0.81±0.1 132.03±0.8 89.34±0.17 5.8±0.98 61.3±1.6 307±9.0 
*
 
Data are expressed as mean±standard deviation of the mean [SD], n=3. 
Table 5: Physicochemical characteristics of transbuccal film by using HPMC E5 (F7-F12) 
Formulation code Thickness 
(mm)






* Swelling Index (%)
 
* Folding endurance* 
F7 0.21±0.07 89.10±0.6 90.23±0.51 7.6±0.98 23.0±4.1 326±4.7 
F8 0.27±0.04 98.91±0.5 95.27±0.47 6.7±0.07 27.0±3.6 319±5.1 
F9 0.55±0.03 103.25±0.3 97.33±0.31 6.9±0.12 48.2±1.1 345±1.8 
F10 0.82±0.02 112.16±0.2 93.82±0.11 6.3±0.83 52.0±2.6 337±3.1 
F11 0.88±0.06 121.36±0.5 88.67±0.61 7.2±1.23 61.3±2.3 312±2.5 
F12 0.91±0.1 128.57±0.3 85.47±0.87 6.4±0.03 56.4±5.2 336±4.5 
*
 
Data are expressed as mean±standard deviation of the mean [SD], n=3. 
Table 6: Physicochemical characteristics of transbuccal film by using chitosan (F13-F18) 
Formulation code Thickness 
(mm)






* Swelling index (%) Folding endurance* * 
F13 0.92±0.03 91.91±0.4 93.51±0.43 5.6±0.67 54.4±5.2 193±1.1 
F14 0.98±0.06 104.25±0.5 94.23±0.71 6.2±0.12 58.2±1.7 194±2.5 
F15 1.15±0.07 103.32±0.2 93.75±0.76 6.5±0.27 63.3±1.6 199±3.7 
F16 1.12±0.53 108.56±0.1 95.80±0.41 6.7±1.63 68.3±1.6 208±0.8 
F17 1.5±0.39 122.46±0.7 92.68±0.73 7.2±0.28 76.5±3.6 176±3.8 
F18 1.4±0.81 128.03±0.4 91.62±0.82 6.5±0.83 73.3±6.1 165±1.9 
*
 
Data are expressed as mean±standard deviation of the mean [SD], n=3. 
As the concentration of polymers increases, both film thickness and 
weight of the patches also increases. Weight of the film ranged from 
89.10±0.6 to 132.03±0.8 mg. Weight and thickness are directly 
related to the accuracy of the dose distribution in the film. The 
thickness of the film ranged from 0.21±0.07 to 132.03±0.8 mm. the 
films of chitosan shown highest thickness. Drug content ranges from 
Sharannavar et al. 




85.47±0.87 to 97.33±0.31. Uniformity in drug content is important 
parameter in formulation which confirm reproducibility of the 
product. The assay of drug content at three different places in each 
film showed that the drug was uniformly distributed throughout the 
films. The surface pH ranged from 5.6 to 7.6 which ensure there is 
no mucosal irritation due to the formulation. 
The swelling index study was carried out to find out the degree of 
swelling of buccal films in simulated saliva solutions. HPMCK4M and 
HPMC E5 films started swelling after 5 min and chitosan after 30 
min when hydrated on agar medium due to the swellable 
hydrophillic polymers. The results shown that as the polymer 
concentration increases the swelling index was also increased. As 
per the study carried out by the authors Pankaj kumar et al., [1] 
swelling of the polymers makes strong secondary hydrogen bonding 
with buccal mucosa and thus results in good mucoadhesion which 
provides unidirectional release of the drug. Chitosan buccal films 
(F13 to F 18) shown high values of swelling index as compared to 
HPMC films (F1 to F12). H. Castan et al., [2] stated that this may be 
due to chitosan when wetted can gain weight and size by 150%. This 
high value of swelling index causes discomforts to the patient. 
All the developed formulations were flexible and shown good folding 
endurance. However, HPMC K4M and HPMC E5 formulations (F1 to 
F12) shown good folding endurance but in case of chitosan 
containing formulations (F13 to F18), the films became brittle, lost 
elasticity as the polymer concentration increased. Hence the folding 
endurance values decreased as the polymer concentration 
increased.  
Ex-vivo residence time 
Residence of film is directly related to the mucoadhesive strength, 
which is consequence of interaction between mucin and polymers. 
Further adequate hydration is required for the polymers to get 
charged and impart sufficient mucoresidence. Ex-vivo residence 
time ranged from 2.2±0.08to 8.2±0.17 h. In the formulations with 
HPMC K4M polymers (table 7) containing films, the presence of 
hydroxyl groups which facilitate uptake of water into polymer 
matrix and enhance mucoadhesiveness. These polymers also form 
viscous liquids when hydrated with increasing their retention time 
over mucosal surfaces, which may lead to adhesive interactions. 
The formulations with HPMC E5 (table 8) shown short period of 
residence time, which might be because of low viscosity of the 
polymer which resulted into weak adhesion. In case of 
formulations with chitosan (table 9), there is interaction between 
positively charged amino group and negatively charged mucin of 
membrane and helps in bioadhesion for longer duration of time. 
 








(N/m2)  * 
% Drug released 
after 6 h
% Drug permeated 
after 6 h* * 
F1 6.1±0.12 40±1.41 3920  97.78±1.08 96.78±1.1 
F2 6.2±0.08 42±0.86 4116 95.32±3.5 94.24±1.0 
F3 6.5±0.10 43±1.07 4214  94.17±0.62 93.27±2.6 
F4 7.2±0.15 44±1.43 4312 92.34±1.4 87.34±4.4 
F5 7.3±0.11 45±1.86 4410 89.24±2.0 77.43±3.0 
F6 7.4±0.13 47±0.88 4606 86.17±1.2 68.42±1.3 
*
 
Data are expressed as mean±standard deviation of the mean [SD], n=3. 








(N/m2)  * 
% Drug released 
after 6 h
% Drug permeated 
after 6 h* * 
F7 2.2±0.08 30±0.64 2940 94.5±1.4 90.45±3.2 
F8 2.3±0.13 31±0.76 3038 92.7±1.1 89.57±3.9 
F9 2.6±0.18 32±0.63 3136 91.32±1.2 86.45±3.0 
F10 2.7±0.16 34±0.35 3332 90.88±1.7 81.37±0.8 
F11 2.7±0.16 36±0.41 3528 89.88±1.7 78.73±1.3 
F12 2.8±0.17 37±0.36 3626 86.47±3.1 71.56±0.5 
*
 
Data are expressed as mean±standard deviation of the mean [SD], n=3. 








(N/m2)  * 
% Drug released after 
6 h
% Drug permeated 
after 6 h* * 
F13 7.2±0.17 54±0.52 5292 76.44±3.1 73.25±1.7 
F14 7.5±0.08 57±0.84 5586 74.15±1.0 69.83±4.8 
F15 7.9±0.12 60±0.57 5880 72.35±2.2 65.23±2.8 
F16 8.1±0.61 62±0.33 6076 71.83±3.6 63.12±3.6 
F17 8.1±0.91 65±0.57 6370 70.79±2.5 60.56±2.6 
F18 8.2±0.17 66±0.43 6468 68.73±1.1 57.34±2.1 
* Data are expressed as mean±standard deviation of the mean [SD], n=3. 
 
Ex-vivo bioadhesion test 
Mucoadhesive strength plays an important role in proper adherence 
of the film to the mucosal surface. Excessive adhesion may cause 
discomfort to the patient leading to the patient in compliance. Hence 
optimum mucoadhesion is required for film for effective therapy.  
The Ex-vivo bioadhesive strength and Detachment force value are 
shown in the above table (7-9). Transbuccal films with HPMC K4M 
(F1-F6); shows good mucoadhesion, which may be attributed to the 
hydration and liquid entrapment in the polymer network, after 
formation of viscous polymeric network, however HPMC E5 (F7-
F12) polymer films shows the weak force of adhesion. According to 
Magdy et al., [12] this might be because of its low viscosity of the 
polymer. Apart from this, hydrophilicity PVP K30 (from Solid 
dispersions which is incorporated in the transbuccal film) might 
further have weakened the force of adhesion. The transbuccal films 
of chitosan (F13-F18) also show good mucoadhesion. According to 
Cui et al. [13] the strong viscoelastic property and structure of 
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chitosan might be attributed to its high mucoadhesive force which 
occurs because of interaction between amino group of chitosan and 
mucin of biomembrane. 
In vitro drug release 
The drug release study was carried out over a period of no longer 
than 6 h given that formulations cannot remain for longer period s 
on the surface of the buccal membrane. 
The drug release profile of formulations is shown in the fig. 2. At the 
end of the 6th h F1 showed highest drug release of 97.78% and F6 is 
86.17%. In case of HPMC E5 formulations, at the end of the 6th
Similar observation is made with HPMC E5 formulations also. 
However initial drug release (30 min) is more as compared to other 
formulations. This might be because of low viscosity of HPMC E5 
polymer as observed by Magdy et al., [12] 
 h F7 
showed highest drug release of 94.5% and F12 is 86.47%. The 
significant decrease in drug release is found as the polymer 
concentration increases in formulations from F1 to F6. Meher et al. 
[2] states that this could be related to the increase in thickness of the 
film with an increase in HPMC concentration. Thus the time requires 
for dissolution medium to penetrate into the polymer chain located 
through the depth of the film increases.  
At the end of the 6th h F13 showed highest drug release of 76.44% 
and F18 is 68.73%. In the case of chitosan containing formulations 
drug release values after completion of 6th
 
 h is lower as compared to 
other formulations. Similar observation is found by author Patel R P 
et al., [1] chitosan is a cationic polymer which might have formed 
complex with PVP K30 (polymer used to prepare solid dispersions 
which is incorporated in the transbuccal films), which is non-ionic 
polymer leading to extension of the drug release. 
 
Fig. 2: Percentage drug release profile of transbuccal films (F1-F18) (Values are expressed as mean±SD, n=3) 
 
 
Fig. 3: Percentage drug permeation profile of transbuccal films (F1-F18) (Values are expressed as mean±SD, n=3) 
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Ex-vivo drug permeation study 
The fig. 3 shows the drug permeation profile of formulations. Drug 
permeated at the 6th h of F1 is 96.78% and F6 is 68.42%. Similarly, F7 is 
90.45 % and F1271.56 %. In case of HPMC polymers, formation of 
hydrogel occurs at the surface of biomembrane, which leads to hydration 
and swelling of mucoadhesive films which promotes diffusion of drug. 
Drug permeated at the end of the 6th
To investigate the release kinetics of drug release from buccal films, 
the in vitro drug release and ex-vivo permeation data were subjected 
to fit various kinetic models using PCP Disso ver 2 software Pune 
India. The r
 h of F13 is 73.25 % and F18 is 57.34 
%. As discussed in the study of swelling index, chitosan films when 
wetted can gain weight and size by 150% due to swelling of 
mucoadhesive films, formation of very thick hydrogen layer leads to the 
longer diffusion path length leading into delayed diffusion. Castan et al. 
[4] states that drug diffusion is delayed in the case of ionic polymers such 
as chitosan as compared to nonionic polymers (HPMC). 
2
Based on results of Drug content, swelling index, folding endurance 
in vitro bioadhesion, in vitro drug release and ex-vivo permeation, we 
can conclude that HPMCK4M formulations (F1-F6) are best 
formulations. The formulation F3 is selected for the further stability 
study. 
and n values are determined. All the buccal films 
showed n values in the range of 0.73 to 0.87, indicating that the drug 
release followed by nonfickian diffusion and the best fit model 
observed to be higuchi model. 
Stability study 
Accelerated stability data is given in table 10. The results of the 
stability study revealed that there is no significant change in drug 
content, in vitro drug release and ex-vivo permeation. 
  
Table 10: Accelerated stability data of the best formulation F3 
Time Drug content % drug released* % drug permeated* * 
Initial 93.80±0.71 93.13±2.15 92.34±1.14 
1 mo 93.21±0.37 92.17±3.17 92.23±1.67 
2 mo 92.34±0.54 92.45±1.13 91.45±2.44 
3 mo 91.46±0.56 91.17±2.23 91.87±1.24 
* Data are expressed as mean±standard deviation of the mean [SD], n=3. 
 
CONCLUSION  
Mucoadhesive films of spraydried LVS were successfully developed 
by using 3 different polymers HPMCK4M, HPMCE5LV and chitosan. 
An in vitro charecterisation result shows that HPMCK4M 
formulations are best formulations. Drug release and permeation 
were found to be nonfickian diffusion and best fit model observed to 
be higuchi model. Stability study data revealed that there is no 
significant change in the drug content, in vitro drug release and ex-
vivo permeation. By using transbuccal mucoadhesive films, it can 
enhance the drug bioavailability by preventing the first-pass 
metabolism thus providing better therapeutic efficacy.  
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